These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7164480)

  • 21. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lipid-reducing basic diet and serum fatty acid levels].
    Reuter W
    Z Gesamte Inn Med; 1980 Sep; 35(18):701-6. PubMed ID: 7445612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lipoproteins and fatty acids--hyperlipoproteinemia and arteriosclerosis].
    Reuter W
    Z Gesamte Inn Med; 1978 Sep; 33(17):622-5. PubMed ID: 706497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in fatty acid composition of the single platelet phospholipids induced by pantethine treatment.
    Gensini GF; Prisco D; Rogasi PG; Matucci M; Neri Serneri GG
    Int J Clin Pharmacol Res; 1985; 5(5):309-18. PubMed ID: 4066081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP; Kurlat MI; Neuman J
    Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 30. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
    Vessby B; Lithell H; Gustafsson IB; Boberg J
    Atherosclerosis; 1980 Jan; 35(1):51-65. PubMed ID: 6989377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of postnatal age and diet on the fatty acid composition of plasma lipid fractions in preterm infants.
    Pita ML; Girón MD; Pérez-Ayala M; DeLucchi C; Martínez Valverde A; Gil A
    Clin Physiol Biochem; 1989; 7(5):238-48. PubMed ID: 2805572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 36. [Fatty acid metabolism in primary hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1979 Oct; 34(20):suppl 287-9. PubMed ID: 398634
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
    Polakowska M; Broda G; Rywik S; Piotrowski W; Bednarska M; Kuźmińska A; Pytlak A; Chotkowska E
    Pol Arch Med Wewn; 1994 Jan; 91(1):9-18. PubMed ID: 8190659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Changes in the fatty acid composition of erythrocyte and platelet membranes after diet therapy in patients with hyperlipoproteinemia type II].
    Korf II; Meshcheriakova VA; Samsonov MA; Chepurnenko NV; Koshechkin VA
    Vopr Med Khim; 1987; 33(3):73-7. PubMed ID: 3630021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia].
    Hrebícek J; Skottová N; Chmela Z; Hrbková M
    Cas Lek Cesk; 1995 Mar; 134(5):141-4. PubMed ID: 7728839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.